Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Income Before Tax

Profit after all operating and non-operating items but before income tax.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$24.15M, compared with -$52.2M a year earlier. Trailing-twelve-month income before tax was -$246.41M.

Context

  • Income before tax amounted to 762355.6% of revenue in FY2025, up 200070.3 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$24.15M or moves back toward the trailing-twelve-month quarterly average of -$61.6M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$24.15M+82.8% QoQ
Last fiscal yearDec 2025
-$274.45M+20.0% YoY
LTMMar 2026
-$246.41M+26.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53.7%——
1 year+20.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(274.45M) USD
Year-over-year change
+20.0%

Income Before Tax vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.3% is the 5th highest of 10, against a peer median of -7.6%.
  • Income before tax amounts to 794858.1% of revenue for LYEL, versus a peer median of 1788.8%.
LYEL Competitors
Income Before Tax for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$27.37M USD+52.6%——
GNLXGenelux CorporationLTM Mar 2026-$31.78M USD-7.7%—397225.0%
AMRNAmarin Corporation plcLTM Mar 2026-$34.72M USD+57.8%—16.2%
ACIUAC Immune S.A.LTM Mar 2026-CHF 66.22M CHF-27.2%—1788.8%
SLNSilence Therapeutics plcLTM Mar 2026-$85.16M USD——9241.5%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$156.4M USD-7.6%——
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$166.01M USD-74.3%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.0%——
CABACabaletta Bio, Inc.LTM Mar 2026-$175.43M USD-38.4%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M USD+26.3%—794858.1%
Peer median (excluding LYEL) —-7.6%—1788.8%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.